PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.73
Negative D/E while AXSM shows 2.95. Joel Greenblatt would look for hidden assets and restructuring catalysts.
-27.48
Net cash position while AXSM shows net debt of 2.39. Joel Greenblatt would examine if this balance sheet advantage creates strategic opportunities.
-1.35
Negative coverage while AXSM shows 20.02. Joel Greenblatt would look for operating improvements and turnaround potential.
0.09
Current ratio below 50% of AXSM's 1.57. Jim Chanos would check for potential working capital crisis.
No Data
No Data available this quarter, please select a different quarter.